SLPI (F6Z7H) Rabbit Monoclonal Antibody #17012

Secretory leukocyte protease inhibitor (SLPI), also known as antileukoproteinase, is a small protein expressed primarily at mucosal surfaces (1), where it helps to protect against inflammation by inhibiting proteases, including elastase, chymotrypsin, and cathepsin G (2,3). SLPI also exerts antimicrobial activity against various Gram-positive and Gram-negative bacteria, some fungi and viruses, and suppresses the production of pro-inflammatory cytokines through NF-kB inhibition (1,4). SLPI has recently been shown to be upregulated in cancer-associated fibroblasts, and extracellular vesicle-encapsulated SLPI levels were reported to be correlated with tumor stage in ovarian cancer patients (5). Higher SLPI expression levels are also correlated with poorer prognosis in other cancer types, including colorectal and breast cancer (6,7). SLPI is essential for normal granulocytic differentiation and may be of therapeutic interest for congenital neutropenia patients (8).